ZTS · 8-K · 20260806PR000038

Regulatory Approval Milestones

Zoetis Inc. · 2026-08-06 · Importance 31 · Surprise 42 · No source text

Zoetis received European Commission marketing authorization in July 2026 for Poulvac Procerta HVT-ND, a poultry vaccine targeting Newcastle and Marek’s disease. Dectomax-CA1 received FDA conditional approval for prevention and treatment of New World screwworm myiasis in beef cattle, and Dectomax received U.S. emergency use authorization across multiple livestock species. The company also reported approvals or label expansions for products in the United States, China, the European Union, Japan, Canada, Switzerland and Great Britain. These approvals expand geographic access and address animal disease and food-supply risks.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiveprobableZoetis received European Commission marketing authorization in July for Poulvac® Procerta® HVT-ND.
revenuepositiveprobableDectomax-CA1 received FDA conditional approval for prevention and treatment of New World screwworm myiasis in beef cattle; Dectomax and…
revenuepositiveprobableVanguard® crLyme received a U.S. label update for effectiveness against subclinical arthritis caused by Borrelia burgdorferi.
revenuepositiveprobableBonqat® was approved in China as an oral medication for acute anxiety and fear in cats related to transportation and veterinary visits.
revenuepositiveprobableSynovex® One Grower gained an expanded U.S. label approval to increase the rate of weight gain in growing beef steers and heifers in dry…
revenuepositiveprobableSuvaxyn® PRRS Needle-Free Microdose vaccine was approved in the EU with a needle-free intramuscular administration claim and a new…
revenuepositiveprobableFostera® Gold PVC MH Flex was approved in Japan to help prevent infection from Mycoplasma hyopneumoniae and Porcine circovirus.